


## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) A composition suitable for oral administration to an animal for the purpose of sequestering one or more lipophilic materials present in the gastrointestinal tract of the animal, wherein the composition comprises a non-digestible, non-absorbable, open-celled polymeric foam comprising a polymeric material; wherein said polymeric foam is a HIPE foam having a density of less than about 0.1 g/cc; wherein said polymeric material is selected from the group consisting of celluloses, chitins, chitosans, natural sponges, synthetic sponges, polyvinyl acetate, polyvinyl alcohol, polyurethanes, polyacrylates, polymethacrylates, polystyrenics, polyolefins, copolymers thereof, and mixtures thereof; and wherein said composition is in a form selected from the group consisting of capsule, pill, caplet, tablet, chewable tablet, suspension, suppository, and combinations thereof.
- 2-5. (Canceled)
6. (Original) The composition according to Claim 1 further comprising a lipase inhibitor.
7. (Canceled)
8. (Previously Presented) The composition according to Claim 6, wherein the lipase inhibitor is selected from the group consisting of 2-amino-4H-3,1-benzoxazin-4-ones; 2-oxy-4H-3,1-benzoxazin-4-ones; 2-thio-4H-3,1-benzoxazin-4-ones; tetrahydrolipstatin and its derivatives; chiral alkylphosphonates; chiral isomers of beta-lactone; and mixtures thereof.

9. (Original) The composition according to Claim 8 wherein at least one of the lipase inhibitors is a compound having the structure:



wherein A is the group



or  $-(CH_2)_5-$ .


10-22. (Canceled)

23. (Previously Presented) A kit comprising:

- (a) a first composition suitable for oral administration comprising a non-digestible, non-absorbable, open-celled polymeric foam comprising a polymeric material; wherein said polymeric foam is a HIPE foam having a density of less than about 0.1 g/cc; wherein said polymeric material is selected from the group consisting of celluloses, chitins, chitosans, natural sponges, synthetic sponges, polyvinyl acetate, polyvinyl alcohol, polyurethanes, polyacrylates, polymethacrylates, polystyrenics, polyolefins, copolymers thereof, and mixtures thereof; and wherein said first composition is in a form selected from the group consisting of capsule, pill, caplet, tablet, chewable tablet, suspension, suppository, and combinations thereof; and
- (b) a second composition comprising a lipase.

24. (Canceled)

25. (Original) The kit according to Claim 23 wherein the second composition comprises a lipase inhibitor selected from the group consisting of 2-amino-4H-3,1-benzoxazin-4-ones; 2-oxy-4H-3,1-benzoxazin-4-ones; 2-thio-4H-3,1-benzoxazin-4-ones; tetrahydrolipstatin and its derivatives; chiral alkylphosphonates; chiral isomers of beta-lactone; and mixtures thereof.
26. (Original) The kit according to Claim 25 wherein the lipase inhibitor is a compound having the structure:



wherein A is the group



or  $-(CH_2)_5-$ .

27. (Previously Presented) A kit comprising:
- (a) a composition suitable for oral administration comprising a non-digestible, non-absorbable, open-celled polymeric foam comprising a polymeric material; wherein said polymeric foam is a HIPE foam having a density of less than about 0.1 g/cc; wherein said polymeric material is selected from the group consisting of celluloses, chitins, chitosans, natural sponges, synthetic sponges, polyvinyl acetate, polyvinyl alcohol, polyurethanes, polyacrylates, polymethacrylates, polystyrenics, polyolefins, copolymers thereof, and mixtures thereof; and wherein said composition is in a form selected from the group consisting of capsule, pill, caplet, tablet, chewable tablet, suspension, suppository, and combinations thereof; and

- (b) information associated with the composition that use of the composition will provide one or more benefits selected from the group consisting of sequestration of lipophilic materials, treatment of gastrointestinal distress, treatment of fecal urgency, treatment of obesity, weight loss, weight control, treatment of hyperlipidemia, treatment of diarrhea, inhibition of anal leakage, reduction of levels of toxic substances, treatment of Type II Diabetes, delay of onset of Type II Diabetes, and combinations thereof.

28. (Canceled)

29. (Previously Presented) A composition suitable for oral administration to an animal for the purpose of sequestering one or more lipophilic materials present in the gastrointestinal tract of the animal, wherein the composition comprises a non-digestible, non-absorbable, open-celled polymeric foam comprising a polymeric material; wherein said polymeric foam is a HIPE foam having:


- (a) a specific surface area per foam volume of at least about  $0.01 \text{ m}^2/\text{cc}$ ; and
- (b) a glass transition temperature ( $T_g$ ) from about  $-40^\circ\text{C}$  to about  $90^\circ\text{C}$ ;

wherein said polymeric material is selected from the group consisting of celluloses, chitins, chitosans, natural sponges, synthetic sponges, polyvinyl acetate, polyvinyl alcohol, polyurethanes, polyacrylates, polymethacrylates, polystyrenics, polyolefins, copolymers thereof, and mixtures thereof; and wherein said composition is in a form selected from the group consisting of capsule, pill, caplet, tablet, chewable tablet, suspension, suppository, and combinations thereof.

30. (Previously Presented) The composition according to Claim 29 further comprising a lipase inhibitor.

31. (Previously Presented) The composition according to Claim 30, wherein the lipase inhibitor is selected from the group consisting of 2-amino-4H-3,1-benzoxazin-4-ones; 2-oxy-4H-3,1-benzoxazin-4-ones; 2-thio-4H-3,1-benzoxazin-4-ones; tetrahydrolipstatin and its derivatives; chiral alkylphosphonates; chiral isomers of beta-lactone; and mixtures thereof.

32. (Previously Presented) The composition according to Claim 31 wherein at least one of the lipase inhibitors is a compound having the structure:



wherein A is the group



or  $-(CH_2)_5-$ .

33. (Previously Presented) A kit comprising:


(a) a first composition suitable for oral administration comprising a non-digestible, non-absorbable, open-celled polymeric foam comprising a polymeric material; wherein said polymeric foam is a HIPE foam having:

- (i) a specific surface area per foam volume of at least about  $0.01 \text{ m}^2/\text{cc}$ ; and
- (ii) a glass transition temperature ( $T_g$ ) from about  $-40^\circ\text{C}$  to about  $90^\circ\text{C}$ ;

wherein said polymeric material is selected from the group consisting of celluloses, chitins, chitosans, natural sponges, synthetic sponges, polyvinyl acetate, polyvinyl alcohol, polyurethanes, polyacrylates, polymethacrylates, polystyrenics, polyolefins, copolymers thereof, and mixtures thereof; and wherein said first composition is in a form selected from the group consisting of capsule, pill, caplet, tablet, chewable tablet, suspension, suppository, and combinations thereof; and

(b) a second composition comprising a lipase inhibitor.

34. (Previously Presented) The kit according to Claim 33 wherein the lipase inhibitor is selected from the group consisting of 2-amino-4H-3,1-benzoxazin-4-ones; 2-oxy-4H-3,1-benzoxazin-4-ones; 2-thio-4H-3,1-benzoxazin-4-ones; tetrahydrolipstatin and its derivatives; chiral alkylphosphonates; chiral isomers of beta-lactone; and mixtures thereof.
35. (Previously Presented) The kit according to Claim 34 wherein the lipase inhibitor is a compound having the structure:



wherein A is the group



or  $-(CH_2)_5-$ .

36. (Currently Amended) A kit comprising:
- (a) a composition suitable for oral administration comprising a non-digestible, non-absorbable, open-celled polymeric foam comprising a polymeric material; wherein said polymeric foam is a HIPE foam having:
- (i) a specific surface area per foam volume of at least about  $0.01 \text{ m}^2/\text{cc}$ ; and
  - (ii) a glass transition temperature ( $T_g$ ) from about  $-40^\circ\text{C}$  to about  $90^\circ\text{C}$ ;

wherein said polymeric material is selected from the group consisting of celluloses, chitins, chitosans, natural sponges, synthetic sponges, polyvinyl acetate, polyvinyl alcohol, polyurethanes, polyacrylates, polymethacrylates, polystyrenics, polyolefins, copolymers thereof, and mixtures thereof; and wherein said composition is in a form selected from the group consisting of

capsule, pill, caplet, tablet, chewable tablet, suspension, suppository, and combinations thereof; and

- (b) information associated with the composition that use of the composition will provide one or more benefits selected from the group consisting of sequestration of lipophilic materials, treatment of gastrointestinal distress, treatment of fecal urgency, treatment of obesity, weight loss, weight control, treatment of hyperlipidemia, treatment of diarrhea, inhibition of anal leakage, reduction of levels of toxic substances, treatment of Type II Diabetes, delay of onset of Type II Diabetes, ~~prevention of Type II Diabetes~~, and combinations thereof.

37. (Previously Presented) The kit according to Claim 36 wherein the composition comprises a lipase inhibitor selected from the group consisting of 2-amino-4H-3,1-benzoxazin-4-ones; 2-oxy-4H-3,1-benzoxazin-4-ones; 2-thio-4H-3,1-benzoxazin-4-ones; tetrahydrolipstatin and its derivatives; chiral alkylphosphonates; chiral isomers of beta-lactone; and mixtures thereof.
38. (Previously Presented) The kit according to Claim 27 wherein the composition comprises a lipase inhibitor selected from the group consisting of 2-amino-4H-3,1-benzoxazin-4-ones; 2-oxy-4H-3,1-benzoxazin-4-ones; 2-thio-4H-3,1-benzoxazin-4-ones; tetrahydrolipstatin and its derivatives; chiral alkylphosphonates; chiral isomers of beta-lactone; and mixtures thereof.